Few decisions in perinatal mental health carry as much emotional weight as whether to take antidepressants in pregnancy or while breastfeeding. Expectant and new parents are often caught between two competing anxieties: fear that medication might harm the baby, and fear that untreated depression or anxiety will. Add in conflicting advice from well-meaning family members, outdated online articles, and clinicians who sometimes disagree with each other, and the result is a decision that feels almost impossible to make with confidence.
This guide is designed to help you think through that decision the way perinatal psychiatrists and reproductive mental health specialists do. We'll examine what the current research actually shows about selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other antidepressants during pregnancy and lactation. We'll also look at the frequently underestimated risks of untreated perinatal depression and anxiety, because that is the true comparison — not medication versus nothing, but medication versus an illness that also affects both parent and child.
Nothing here replaces individualized medical advice. But a well-informed patient asks better questions, tolerates uncertainty more gracefully, and partners more effectively with a prescriber. That is the goal.
Key Takeaways
- Untreated perinatal depression is not a neutral baseline — it carries measurable risks to both parent and child, including preterm birth, impaired bonding, and maternal mortality.
- SSRIs are the most-studied antidepressants in pregnancy, and absolute risks of major birth defects remain low; sertraline is often first-choice in lactation due to minimal milk transfer.
- Stopping medication before pregnancy raises relapse risk to ~68% in women with recurrent depression, compared to ~26% among those who continue.
- Most antidepressants are compatible with breastfeeding — you rarely have to choose between medication and nursing.
- Treatment decisions are individualized, based on symptom severity, personal history, and what has previously worked for you.
- Suicidal thoughts or postpartum psychosis are medical emergencies — call 988 or the National Maternal Mental Health Hotline (1-833-TLC-MAMA).
How Common Is Perinatal Depression, Really?
Perinatal mood and anxiety disorders (PMADs) are the most common complication of pregnancy and childbirth. About 1 in 8 women in the U.S. experience symptoms of postpartum depression, and roughly 1 in 7 experience a depressive episode during pregnancy or the year after birth. Including subthreshold and anxiety symptoms, that figure climbs to 1 in 5.
The Centers for Disease Control and Prevention estimates that about 1 in 8 women in the United States experience symptoms of postpartum depression, and roughly 1 in 7 experience a depressive episode during pregnancy or the year after birth [CDC, 2023]. The American College of Obstetricians and Gynecologists puts the lifetime prevalence of perinatal depression at up to 1 in 5 birthing people when subthreshold and anxiety symptoms are included [ACOG, 2023].
The National Institute of Mental Health notes that perinatal depression is distinct from the transient "baby blues" that affect up to 80% of new mothers in the first two weeks postpartum. Perinatal depression is more severe, longer-lasting, and can begin during pregnancy or up to a year after delivery [NIMH, 2024]. Untreated, it can persist for years and elevate the risk of future depressive episodes.
Anxiety disorders are at least as common. Research summarized by the Anxiety and Depression Association of America suggests that generalized anxiety, panic disorder, and obsessive-compulsive symptoms are all elevated during pregnancy and the postpartum period, and often go undiagnosed because clinicians screen primarily for depression [ADAA, 2023].
Why does this matter before you weigh medication?
Before considering any drug's risk profile, it helps to know two things: perinatal depression is common, and it is treatable. According to the American Psychological Association, psychotherapy, medication, or a combination can produce meaningful improvement in most patients, and early treatment leads to better outcomes for both parent and child [APA, 2022].
The Risks of Untreated Perinatal Depression
The most common mistake in this conversation is comparing antidepressants to an imaginary baseline of "nothing happening." Untreated maternal depression is not a neutral state. It carries measurable risks — including preterm birth, low birth weight, impaired bonding, and increased maternal mortality — that must be placed on the same scale as medication risks.
What are the risks to the pregnant person?
- Suicide is a leading cause of maternal death. The CDC's Maternal Mortality Review Committees have found that mental health conditions, including suicide and overdose, account for roughly 22% of pregnancy-related deaths in the U.S. — more than hemorrhage or hypertensive disorders [CDC, 2022].
- Poorer prenatal self-care. Depression is associated with reduced attendance at prenatal appointments, inadequate nutrition, and higher rates of smoking, alcohol, and substance use [ACOG, 2023].
- Increased risk of preeclampsia and gestational diabetes in some studies, likely mediated by stress hormones and inflammation [NIH, 2022].
What are the risks to the baby?
- Preterm birth and low birth weight. A meta-analysis cited by the World Health Organization found that antenatal depression is associated with a significantly increased risk of preterm delivery and low birth weight [WHO, 2022].
- Impaired mother-infant bonding. Postpartum depression can interfere with attunement, responsive feeding, and early attachment [Mayo Clinic, 2023].
- Long-term developmental effects. Children of mothers with untreated depression show, on average, higher rates of behavioral problems, cognitive delays, and later mental health difficulties [Harvard Medical School, 2022].
The point is not to alarm anyone already struggling. It is to correct a widespread misconception: choosing not to treat depression is itself a choice with consequences, not a way to avoid risk.
What We Know About Antidepressants in Pregnancy
Antidepressants — most commonly SSRIs — are among the most studied classes of medication in pregnancy. Decades of observational data suggest that overall absolute risks of major malformations are low, and most SSRIs (with the notable exception of paroxetine) are considered reasonable options when clinically indicated.
That level of research exists partly because so many pregnant people take them: CDC data suggest that roughly 6–8% of pregnant women in the U.S. fill an antidepressant prescription at some point during pregnancy [CDC, 2023].
What does the research show about SSRIs?
Selective serotonin reuptake inhibitors include sertraline (Zoloft), fluoxetine (Prozac), citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil), and fluvoxamine (Luvox). The American College of Obstetricians and Gynecologists and the American Psychiatric Association generally consider SSRIs — with the notable caveat around paroxetine — reasonable options during pregnancy when clinically indicated [ACOG, 2023; APA, 2023]. For a broader primer on how these agents work, our overview of Antidepressants Explained: SSRIs, SNRIs & Atypicals Guide 2025 is a good companion read.
Key findings from the research base:
- Major congenital malformations: The overall absolute risk of birth defects with SSRI exposure is low. Most large studies, including those reviewed by the CDC's National Birth Defects Prevention Study, have not found a meaningful increase in overall malformation rates with most SSRIs. Paroxetine has been associated with a small increased risk of cardiac defects in some studies, which is why it is generally avoided in pregnancy when alternatives exist [CDC, 2022].
- Persistent pulmonary hypertension of the newborn (PPHN): Early studies suggested a link between late-pregnancy SSRI use and PPHN, a serious lung condition. Larger subsequent analyses found the absolute risk remains very low — on the order of 3 per 1,000 exposed infants compared to about 2 per 1,000 unexposed — and the FDA has updated its position accordingly [NIH, 2022].
- Neonatal adaptation syndrome: Roughly 20–30% of infants exposed to SSRIs in late pregnancy show transient symptoms such as jitteriness, mild respiratory distress, feeding difficulty, or irritability, typically resolving within days without treatment [Mayo Clinic, 2023].
- Autism and ADHD: Early observational studies raised concerns about SSRI exposure and later neurodevelopmental disorders. However, more rigorous sibling-controlled analyses — which account for shared genetics and environment — have largely attenuated or eliminated these associations, suggesting that maternal depression itself, rather than the medication, may drive most of the observed risk [Johns Hopkins Medicine, 2023].
What about SNRIs, bupropion, and other classes?
Serotonin-norepinephrine reuptake inhibitors such as venlafaxine (Effexor) and duloxetine (Cymbalta) have a smaller evidence base than SSRIs but no strong signal for major malformations. Bupropion (Wellbutrin) has been studied more extensively due to its use for smoking cessation in pregnancy; current evidence does not support significant teratogenic effects [APA, 2023].
Tricyclic antidepressants, once first-line, are now used less frequently due to overdose risk and side effect burden, but they can be appropriate in specific cases. Monoamine oxidase inhibitors are generally avoided in pregnancy due to interactions with obstetric medications.
Should I stop antidepressants before trying to conceive?
A landmark study followed women with a history of major depression who were euthymic on antidepressants at conception. Those who discontinued medication had a relapse rate of about 68% during pregnancy, compared to 26% among those who continued [NIH, 2022]. This finding fundamentally reshaped clinical practice: for many patients with a history of severe or recurrent depression, stopping medication introduces substantial risk without eliminating exposure — because a relapsed depression is itself an exposure. If you and your prescriber decide tapering makes sense, our clinician-informed guide to how to taper off antidepressants safely outlines a step-down timeline.
Antidepressants and Breastfeeding
The breastfeeding conversation is often more reassuring than patients expect. Most antidepressants are considered compatible with breastfeeding, and the transfer of medication into human milk is generally low. Sertraline is typically the first-line choice because infant serum levels are often undetectable.
Why is sertraline the frequent first choice?
Sertraline is often considered the SSRI of choice during lactation because it is transferred into breast milk in very low concentrations, and infant serum levels are typically undetectable or extremely low [Mayo Clinic, 2023]. Paroxetine and fluvoxamine also have low milk transfer. Fluoxetine, by contrast, has a longer half-life and its active metabolite can accumulate in infants, particularly newborns, though it is still used when clinically appropriate.
How do clinicians weigh lactation risks?
The National Institutes of Health's LactMed database — a widely used reference for clinicians — synthesizes the peer-reviewed literature on medications and lactation and generally rates most SSRIs and SNRIs as compatible with breastfeeding, with monitoring for infant sedation, feeding problems, or irritability [NIH, 2024].
The Academy of Breastfeeding Medicine and the American Academy of Pediatrics emphasize that the well-documented benefits of breastfeeding — for infant immunity, digestion, and bonding, and for maternal cardiovascular and metabolic health — should be weighed alongside medication considerations, not sacrificed unnecessarily [AAP, 2022].
What are practical steps for nursing parents?
- Discuss timing of doses with your prescriber; for some medications, taking the dose immediately after a feed may modestly reduce infant exposure at peak concentration.
- Watch for changes in infant sleep, feeding, tone, or alertness, and report them to your pediatrician.
- Premature infants and those with medical conditions may metabolize medications differently and warrant closer monitoring.
- Do not stop a medication abruptly to breastfeed — discontinuation syndromes and relapse both carry their own risks.
How to Actually Make the Decision
Because every pregnancy and every history is unique, there is no universal answer. But there is a repeatable framework: assess severity, consider therapy as a first line for milder cases, choose the medication most likely to work for you, use an effective dose, and involve a multidisciplinary team.
1. How do I assess severity and history?
The National Alliance on Mental Illness recommends that decisions about perinatal psychotropic medication account for the severity, duration, and recurrence of past episodes, as well as any history of suicidality, hospitalization, or psychosis [NAMI, 2023]. Someone with a single, mild depressive episode a decade ago faces a very different calculation than someone with recurrent, severe depression and prior postpartum psychosis.
2. When is psychotherapy the right first line?
Interpersonal therapy (IPT) and cognitive behavioral therapy (CBT) both have strong evidence for perinatal depression. The U.S. Preventive Services Task Force recommends counseling interventions for pregnant and postpartum people at elevated risk of perinatal depression, based on trials showing meaningful risk reduction [ODPHP, 2023]. For mild to moderate depression, evidence-based therapy alone may be sufficient. For moderate to severe symptoms — or when therapy alone has not produced remission — combining therapy with medication is often most effective. If you want to see how those approaches compare head-to-head, our review of Antidepressants vs Therapy: What Meta-Analyses Really Show walks through the outcome data.
3. How do you choose the right medication?
The best antidepressant in pregnancy is often the one that has previously worked well for the patient. Switching from an effective medication to a "safer-sounding" alternative can precipitate relapse, which is itself the exposure most strongly linked to poor outcomes. This is why perinatal psychiatrists frequently continue a patient's pre-pregnancy medication rather than switching.
4. Why is dose adjustment often necessary?
Undertreatment is a common pitfall. Because blood volume increases by roughly 40–50% in pregnancy and hepatic metabolism accelerates, some patients actually require dose increases in the third trimester to maintain the same therapeutic blood level [Cleveland Clinic, 2023]. A dose that felt "just right" pre-pregnancy may become subtherapeutic later.
5. Who should be on the care team?
Ideally, obstetric, psychiatric, and pediatric providers should be aware of the plan. Programs such as the MGH Center for Women's Mental Health and state-level perinatal psychiatry access programs (like Massachusetts's MCPAP for Moms and its counterparts in many states) exist specifically to help general clinicians manage these cases. SAMHSA also maintains the National Maternal Mental Health Hotline (1-833-TLC-MAMA), staffed by counselors trained in perinatal mental health [SAMHSA, 2024].
Special Situations Worth Naming
Certain conditions — bipolar disorder, prior postpartum psychosis, and severe OCD — require specialized planning that goes beyond standard antidepressant algorithms. Newer postpartum-specific medications may also expand the toolkit.
What if I have bipolar disorder?
If there is any history of manic or hypomanic episodes, antidepressant monotherapy can trigger mood destabilization. The Depression and Bipolar Support Alliance emphasizes that perinatal bipolar disorder requires specialized management, often with mood stabilizers rather than antidepressants alone, and postpartum psychosis is a psychiatric emergency [DBSA, 2023].
What about anxiety disorders and OCD?
SSRIs are first-line for perinatal anxiety and obsessive-compulsive disorder. Benzodiazepines are sometimes used short-term but carry their own considerations for late pregnancy and lactation and are generally avoided as a long-term strategy.
What if I had prior postpartum depression or psychosis?
A prior severe postpartum episode substantially raises the risk of recurrence. Prophylactic treatment beginning in late pregnancy or immediately postpartum is often recommended and may prevent a devastating recurrence.
What role do newer postpartum-specific treatments play?
The FDA has approved brexanolone (Zulresso) and zuranolone (Zurzuvae), neuroactive steroid modulators specifically indicated for postpartum depression. These are not appropriate for every patient — and access and cost remain barriers — but they represent an important expansion of the toolkit. Discuss them with a perinatal psychiatrist if you are exploring options [NIMH, 2024].
Common Myths Worth Retiring
Several persistent myths shape how patients approach this decision — and most steer them in unhelpful directions. Setting them straight is part of good perinatal care.
- "Natural is safer." St. John's wort, high-dose omega-3s, and various supplements are not necessarily safer in pregnancy — they are simply less studied, and some have known drug interactions.
- "If I just try harder, I can push through." Depression is a medical illness with biological underpinnings. Willpower is not a treatment, and framing it that way delays care.
- "Medication means I've failed as a mother." The evidence points in the opposite direction: treating perinatal depression is one of the most protective things a parent can do for their child's development [Harvard Medical School, 2022].
- "I have to choose between medication and breastfeeding." For the vast majority of antidepressants, this is a false choice. Most are compatible with breastfeeding [NIH, 2024].
Supporting Yourself Through the Decision
Even with the best information, this decision is emotionally hard. Naming the distress, bringing a support person to appointments, and revisiting the plan at each trimester can meaningfully reduce decisional fatigue.
- Name the decisional distress. The uncertainty itself is stressful, and stress worsens depression. Give yourself permission to acknowledge that.
- Bring a partner or trusted person to appointments. Depression narrows attention; a second listener catches nuances you may miss.
- Ask your prescriber to state their confidence level. "Based on the current evidence, how confident are you in this recommendation?" is a fair question and often yields more useful information than a simple recommendation.
- Reassess regularly. The decision is not static. Symptoms, trimesters, and postpartum realities all shift. A plan set at 12 weeks may need updating at 32 weeks or six weeks postpartum.
- Practice self-compassion. Mental Health America notes that self-criticism during the perinatal period is itself a symptom of many PMADs, and treating yourself with the kindness you would offer a friend is part of recovery [MHA, 2023].
When to Seek Urgent Help
Regardless of what you and your clinician decide about medication, some symptoms require immediate attention. Contact your provider, go to an emergency room, or call the 988 Suicide and Crisis Lifeline (or the National Maternal Mental Health Hotline at 1-833-TLC-MAMA) if you experience:
- Thoughts of harming yourself or your baby
- Feelings that your baby would be better off without you
- Hallucinations, delusions, or extreme confusion (possible postpartum psychosis — a medical emergency)
- Inability to sleep even when the baby is sleeping, combined with racing thoughts
- A sense that you cannot go on
The Bottom Line
The question is rarely "medication or no medication." It is "which combination of treatments best protects both parent and child across pregnancy and the postpartum year?" For many people, that combination includes an antidepressant. For others, therapy alone is enough. For a smaller group, more intensive interventions — including perinatal-specific medications, higher levels of care, or inpatient support — are the right answer.
What the evidence consistently shows is that untreated perinatal depression is not the safe default. It carries real risks to parent and baby, and it responds well to treatment when treatment is offered. The most protective thing you can do — for yourself and for your child — is to work with clinicians who take perinatal mental health seriously, ask good questions, and make an individualized plan you can revisit as circumstances change.
You are not alone in this, and you are not choosing between being a good parent and getting well. Getting well is being a good parent.
Frequently Asked Questions
Are SSRIs safe to take during pregnancy?
Most SSRIs are considered reasonable options during pregnancy when clinically indicated. Large studies have not shown meaningful increases in overall birth defect rates for most SSRIs, though paroxetine is generally avoided due to a small associated risk of cardiac defects. Absolute risks of complications remain low, and clinicians increasingly weigh them against the well-documented harms of untreated maternal depression.
Which antidepressant is safest while breastfeeding?
Sertraline (Zoloft) is often the first choice for breastfeeding parents because it transfers into breast milk in very low concentrations and infant serum levels are typically undetectable. Paroxetine and fluvoxamine also have low milk transfer. Fluoxetine can accumulate in newborns due to its long half-life but is still used when clinically appropriate.
What happens if I stop my antidepressant before getting pregnant?
In women with a history of recurrent major depression, stopping antidepressants around conception led to a relapse rate of about 68% during pregnancy, compared to 26% among those who continued. Relapse is itself an exposure with real risks to pregnancy outcomes, so decisions to discontinue should be made carefully with a prescriber and, when possible, before conception rather than reactively.
Do antidepressants cause autism or ADHD in children?
Early observational studies raised concerns about SSRI exposure and neurodevelopmental disorders, but more rigorous sibling-controlled analyses have largely attenuated or eliminated these associations. Current evidence suggests that untreated maternal depression itself, rather than SSRI exposure, likely drives most of the observed risk.
Can I take antidepressants if I have bipolar disorder and am pregnant?
Antidepressant monotherapy can destabilize mood in people with bipolar disorder and may trigger mania or mixed episodes. Perinatal bipolar disorder typically requires specialized management with mood stabilizers, and postpartum psychosis is a psychiatric emergency. If you have any history of manic or hypomanic symptoms, work with a perinatal psychiatrist before starting or continuing an antidepressant.
Do I need a higher dose of my antidepressant in the third trimester?
Sometimes, yes. Blood volume increases by 40–50% in pregnancy and hepatic metabolism accelerates, which can reduce therapeutic blood levels of some medications. A dose that felt right pre-pregnancy may become subtherapeutic later, so clinicians monitor symptoms closely and may adjust the dose upward in the second or third trimester.
Where can I get urgent perinatal mental health support?
Call the National Maternal Mental Health Hotline at 1-833-TLC-MAMA (staffed 24/7 by counselors trained in perinatal mental health) or the 988 Suicide and Crisis Lifeline for immediate support. Go to an emergency room if you have thoughts of harming yourself or your baby, or symptoms suggestive of postpartum psychosis such as hallucinations, delusions, or extreme confusion.
References
American Academy of Pediatrics (2022). Breastfeeding and the Use of Human Milk. https://publications.aap.org/pediatrics/article/150/1/e2022057988
American College of Obstetricians and Gynecologists (2023). Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum. https://www.acog.org/clinical/clinical-guidance/clinical-practice-guideline/articles/2023/06/treatment-and-management-of-mental-health-conditions-during-pregnancy-and-postpartum
American Psychiatric Association (2023). What Is Peripartum Depression? https://www.psychiatry.org/patients-families/peripartum-depression/what-is-peripartum-depression
American Psychological Association (2022). Postpartum Depression: Causes, Symptoms, Risk Factors, and Treatment. https://www.apa.org/topics/women-girls/postpartum-depression
Anxiety and Depression Association of America (2023). Perinatal Anxiety and Depression. https://adaa.org/find-help/by-demographics/women/postpartum
Centers for Disease Control and Prevention (2022). Pregnancy-Related Deaths: Data from Maternal Mortality Review Committees. https://www.cdc.gov/reproductivehealth/maternal-mortality/erase-mm/mmr-data-brief.html
Centers for Disease Control and Prevention (2023). Depression Among Women. https://www.cdc.gov/reproductivehealth/depression/index.htm
Cleveland Clinic (2023). Antidepressants and Pregnancy: What You Need to Know. https://my.clevelandclinic.org/health/diseases/postpartum-depression
Depression and Bipolar Support Alliance (2023). Bipolar Disorder and Pregnancy. https://www.dbsalliance.org/education/bipolar-disorder/
Harvard Medical School (2022). Perinatal Depression: Maternal and Child Outcomes. https://www.health.harvard.edu/blog/postpartum-depression-more-than-baby-blues-202111022626
Johns Hopkins Medicine (2023). SSRIs in Pregnancy: What the Research Shows. https://www.hopkinsmedicine.org/health/conditions-and-diseases/postpartum-depression
Mayo Clinic (2023). Antidepressants: Safe During Pregnancy? https://www.mayoclinic.org/healthy-lifestyle/pregnancy-week-by-week/in-depth/antidepressants/art-20046420
Mental Health America (2023). Postpartum Disorders. https://mhanational.org/conditions/postpartum-disorders
National Alliance on Mental Illness (2023). Pregnancy, Postpartum, and Mental Health. https://www.nami.org/your-journey/individuals-with-mental-illness/women-and-mental-health/
National Institute of Mental Health (2024). Perinatal Depression. https://www.nimh.nih.gov/health/publications/perinatal-depression
National Institutes of Health (2022). Antidepressant Use During Pregnancy: Risks and Benefits. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314102/
National Institutes of Health (2024). LactMed: Drugs and Lactation Database. https://www.ncbi.nlm.nih.gov/books/NBK501922/
Office of Disease Prevention and Health Promotion (2023). USPSTF Recommendation: Perinatal Depression Preventive Interventions. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/perinatal-depression-preventive-interventions
Substance Abuse and Mental Health Services Administration (2024). National Maternal Mental Health Hotline. https://mchb.hrsa.gov/national-maternal-mental-health-hotline
World Health Organization (2022). Guide for Integration of Perinatal Mental Health in Maternal and Child Health Services. https://www.who.int/publications/i/item/9789240057142